ContributorsPublishersAdvertisers

Xenon Pharma Shares Jump After Epilepsy Treatment Phase 2 Data Meets Primary Endpoint

Business Insider
 2021-10-04

Cover picture for the articleXenon Pharmaceuticals Inc (NASDAQ:XENE) has reported topline results from the Phase 2b X-TOLE trial evaluating XEN1101 as an adjunctive treatment in adult patients with focal epilepsy. The trial met its primary efficacy endpoint with XEN1101, demonstrating a statistically significant and dose-dependent reduction...

markets.businessinsider.com

Comments / 0

Comments / 0